Payment overview · 2025
General Payments
$1,179.93
42 reported records · 12 companies
Healthcare provider profile · identity verified
Jawad Thamer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1972573731
Verified facts
What the public records show
CMS Open Payments records show Jawad Thamer, M.D. received $1,179.93 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Genotropin by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.34 | 16.8% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $190.22 | 16.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $172.16 | 14.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.57 | 12.7% | 7 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.74 | 10.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.77 | 7.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.43 | 5.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.59 | 5.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.95 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.39 | 3.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.02 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.75 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,179.93 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $126.96 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.27 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.48 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.38 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.38 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.48 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.45 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.09 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $46.95 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $46.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 314 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
314 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 123 |
| Eliquis | Apixaban | 314 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 65 |
| Gabapentin | Gabapentin | 202 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 54 |
| Losartan Potassium | Losartan Potassium | 173 | 64 |
| Alendronate Sodium | Alendronate Sodium | 165 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 45 |
| Metformin Hcl | Metformin Hcl | 136 | 40 |
| Omeprazole | Omeprazole | 134 | 40 |
| Januvia | Sitagliptin Phosphate | 133 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 57 |
| Potassium Chloride | Potassium Chloride | 130 | 38 |
| Lisinopril | Lisinopril | 115 | 37 |
| Famotidine | Famotidine | 112 | 38 |
| Furosemide | Furosemide | 106 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 25 |
| Jardiance | Empagliflozin | 91 | 18 |
| Carvedilol | Carvedilol | 90 | 30 |
| Allopurinol | Allopurinol | 86 | 25 |
| Levetiracetam | Levetiracetam | 83 | 15 |
| Methylprednisolone | Methylprednisolone | 81 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 23 |
| Sertraline Hcl | Sertraline Hcl | 73 | 25 |
| Trazodone Hcl | Trazodone Hcl | 69 | 17 |
| Buspirone Hcl | Buspirone Hcl | 66 | 14 |
| Metformin Hcl Er | Metformin Hcl | 62 | 23 |
| Mirtazapine | Mirtazapine | 62 | 20 |
| Ozempic | Semaglutide | 62 | 17 |
| Baclofen | Baclofen | 59 | suppressed |
| Azithromycin | Azithromycin | 55 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 29 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | 15 |
| Donepezil Hcl | Donepezil Hcl | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Methocarbamol | Methocarbamol | 48 | 23 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Simvastatin | Simvastatin | 42 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 19 |
| Amoxicillin | Amoxicillin | 40 | 33 |
| Lactulose | Lactulose | 39 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 16 |
| Lacosamide | Lacosamide | 36 | suppressed |
| Calcitriol | Calcitriol | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 12 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 13 |
| Ursodiol | Ursodiol | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 11 |
| Naproxen | Naproxen | 31 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Novolog Flexpen | Insulin Aspart | 19 | 13 |
| Prednisone | Prednisone | 19 | 15 |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Genotropin | Somatropin | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,179.93 · 42 records | Amgen Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, TEPEZZA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error